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Background: Delayed onset muscle soreness (DOMS) due to eccentric muscle activity is associated with
inflammatory responses and production of reactive oxygen species (ROS) that sustain both inflammation and
oxidative stress. Curcumin, a powerful promoter of anti-oxidant response, is one of the best-investigated natural
products, and is now commercially available as a lecithin delivery system (Meriva®, Indena SpA, Milan) with
improved bio-availability. The aim of this study was to test whether curcumin could attenuate damage from
oxidative stress and inflammation related to acute muscle injury induced by eccentric continuous exercise
Methods: This was a randomised, placebo-controlled, single-blind pilot trial. Twenty male healthy, moderately
active volunteers were randomised to curcumin given as the Phytosome® delivery system 1 g twice daily (200 mg
curcumin b.i.d.) or matching placebo. Supplementation was initiated 48 hours prior to a downhill running test and
was continued for 24 hours after the test (4 days in total). Muscle damage was quantified by magnetic resonance
imaging, laboratory tests and histological analyses on muscle samples obtained 48 hours after the test. Patient-reported
pain intensity was also recorded.
Results: Subjects in the curcumin group reported less pain in the lower limb as compared with subjects in the
placebo group, although significant differences were observed only for the right and left anterior thighs.
Significantly fewer subjects in the curcumin group had MRI evidence of muscle injury in the posterior or medial
compartment of both thighs. Increases in markers of muscle damage and inflammation tended to be lower in the
curcumin group, but significant differences were only observed for interleukin-8 at 2 h after exercise. No
differences in markers of oxidative stress and muscle histology were observed
Conclusions: Curcumin has the potential for preventing DOMS, as suggested by its effects on pain intensity and
muscle injury. Larger studies are needed to confirm these results and further clarify the mechanism of action of
curcumin.
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Delayed onset muscle soreness (DOMS) is a combination
of muscle pain and stiffness occurring several hours after
unaccostumed exercise, particularly when eccentric muscle
activity is involved [1]. Both physically inactive individuals
and athletes are familiar with DOMS, which may limit
physical function for several days after exercise [2]. Over
the past two decades, a large number of studies have been
conducted to test different strategies for preventing DOMS
[3-7], but no specific single intervention has been conclu-
sively demonstrated to be effective. DOMS is seemingly
related to muscle damage from eccentric exercise, like
downhill walking, where contracting muscles are forcibly
lengthened [8]. This mechanical stress triggers an inflam-
matory response and the production of reactive oxygen
species (ROS) that sustain inflammation and oxidative
stress by promoting the activation of transcription factors
like the nuclear factor-κB (NF—κB), a pro-inflammatory
master switch that controls the production of inflam-
matory markers and mediators [9]. Inflammation and
oxidative stress lead to neutrophil accumulation and an
increased production of the “inflammatory soup” of oxi-
dative enzymes, cytokines and chemokines [9-11]. This
eventually overcomes the antioxidant capacity of the
body [12], ultimately resulting in muscle injury and
DOMS. Cellular disruption is associated to direct activa-
tion and sensibilization of the transient receptor potential
(TRP) ion channel family member TRPV1 via acidification
and the liberation of inflammatory eicosanoids. This in
turn sustains inflammation by liberation of inflammatory
peptides and triggers the generation of a pain sensation
(for a review, see [13]).
As a constituent of turmeric (Curcuma longa L.), curcu-
min (diferuloylmethane) has been used for centuries in
the traditional medicine of India and the Far East [14,15].
Curcumin, a powerful promoter of anti-oxidant response
[16], is one of the best investigated natural products [17],
and is now commercially available in a lecithin delivery
system (Meriva®, Indena SpA, Milan) that improves curcu-
minoids bio-availability. This formulation has accumulated
significant clinical documentation of efficacy in various
conditions triggered and/or sustained by chronic inflam-
mation, like diabetic microangiopathy and retinopathy
[18], central serous chorioretinopathy [19], benign pros-
tatic hyperplasia [20], chemotherapy-related adverse
effects in cancer patients [21] and osteoarthritis [22].
In addition, curcumin as Meriva® was also recently val-
idated as an analgesic agent with potency at least com-
parable to that of acetaminophen [23].
Several studies have investigated the mechanisms by
which curcumin exerts its beneficial effect. Early experi-
mental study demonstrated that curcumin suppresses
the activation of NF—κB [24,25], an effect of critical
relevance in DOMS relief, since NF—κB appears to beinvolved in the regulation of proteolysis and inflamma-
tion in muscle [26]. Therefore, inhibition of NF—κB by
curcumin may result in a muscle-protective effect. Con-
sistently, it has been suggested that curcumin may prevent
loss of muscle mass during sepsis and endotoxaemia and
may stimulate muscle regeneration after traumatic injury
[26,27]. Other mechanisms possibly responsible for the
anti-inflammatory and anti-oxidant properties of curcu-
min include induction of heat-shock response [28], reduc-
tion in the expression of the pro-inflammatory enzyme
cyclooxygenase-2 (COX-2) [29] and promotion of the
antioxidant response by activation of the transcription
factor Nrf2 [30]. Experimental evidence indicates that
curcumin can reduce inflammation and decrease some
of the negative effects associated with eccentric exercise-
induced muscle damage, including the release of pro-
inflammatory cytokines and markers of muscle injury
like creatine kinase (CK) [31]. These observations pro-
vided a rationale for evaluating if curcumin, administered
as a lecithin formulation (Meriva®) to improve absorption,
could attenuate damage from oxidative stress and inflam-
mation related to acute muscle injury induced by eccentric
continuous exercise.
Methods
The study was a randomised, placebo-controlled, single-
centre, single-blind pilot trial. It was carried out in accord-
ance with the Declaration of Helsinki, and was approved
by the local Ethics Committee of the Consell Català de
l’Esport (0099S/ 4882/2010).
The study was carried out at the Sports Physiology Dept.
of the Olympic Training Center “Centre d’Alt Rendiment”
of Sant Cugat del Vallés, Barcelona, Spain.
Subjects
Twenty male healthy, moderately active (regular aerobic
exercise for at least 4 hours per week), non-smoking vol-
unteers with no known musculoskeletal pathology were
recruited. Subjects had to have a maximal oxygen con-
sumption (VO2max) of at least 35 ml/kg, as assessed by
the maximal treadmill exercise test. Subjects were ex-
cluded if they met one or more of the following exclusion
criteria: treatment with anti-inflammatory/analgesic/
antioxidant drugs in the previous month, abnormal liver
or renal function tests, laboratory findings suggestive of an
active inflammatory or infectious process and presence of
any known disease.
Proper eligibility of all subjects was evaluated by a
comprehensive medical history and physical examination
by a sports medicine physician.
Supplement
Subjects were randomised (1:1) to curcumin given as the
Phytosome® delivery system (Meriva®, Indena S.p.A. Milan,
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twice a day) at breakfast and dinner, or a matching pla-
cebo. Supplementation was initiated 48 hours prior to the
test and was continued for 24 hours after the test (4 days
in total). Study subjects and physicians performing the
radiologic and laboratory assessments were blinded to
treatment, whereas the sports medicine physicians in-
volved in exercise testing were not.
Exercise testing
Maximal exercise test
Each participant completed a standardized maximal tread-
mill exercise test. A fixed treadmill grade (3%) was main-
tained throughout the test. The treadmill speed was
initially set at 6 km/h, and increased by 1 km/h each mi-
nute until maximum sustainable effort (muscle fatigue or
stabilisation/decline in VO2max) [32,33]. Maximal speed
(Spdmax), the speed at the anaerobic threshold (Spdat) and
the VO2max were recorded for each participant. The tests
were completed on a motorised treadmill (ERGelek EG2,
Vitoria-Gasteiz, Spain). Expired air was sampled using
indirect calorimetric system (Master Screen CPX, Erich
Jaeger, Wurzburg, Germany).
Eccentric muscle injury protocol
A downhill running test modified from the protocols
described by Nurenberg et al. [34] and Malm et al. [35]
was used to induce the eccentric muscle injury. After a
10-min warm-up at a speed chosen by the subject, sub-
jects ran downhill (treadmill grade −10%) at a constant
speed for 45 minutes. Running speed during the 45-min
exercise was to be maintained at the anaerobic threshold,
which was determined prior to the test by measurement
of lactate concentration in capillary blood during a 5-min
run at a treadmill inclination of 3%. A speed correspond-
ing to a lactate concentration of 3.5-5 mmol/L was consid-
ered appropriate and therefore maintained throughout the
exercise protocol. Subjects performed ten-min exercise
bouts during the week prior to the study day (days −7
and −5) to familiarize with the exercise protocol and to
break down more susceptible muscle fibres, in order to
achieve similar fibre composition and standardize the
baseline level in all subject [36,37]. One hour before theFigure 1 STIR sectional image of both thighs in the middle third. Asteeccentric injury protocol all subjects received an oral
nutritional supplement containing 25 to 30 g of carbohy-
drates and 2–4 g of protein. Also, hydration was assured
by consumption of approximately 500 mL of mineral
water from 30 min. prior to the start of the test. Sub-
jects were allowed to drink water during the test.
Magnetic resonance imaging (MRI)
A high magnetic field system was used (Signa 1.5 T, G.E.
Milwaukee, WI, USA). Images were acquired 48 hours
after exercise, with the subjects in the supine decubitus
position. Both thighs were explored. The diagnosis was
based on MRI signal alterations in any muscular group
both in the flexor and the extensor compartment, as well
as on signal asymmetry as compared with the contralat-
eral homonymous muscular group. The radiologist was
blinded to the treatment group. Five non-contiguous
axial imaging slices (2-mm thickness, 2-mm gap) were
selected. In order to quantify muscle injury, each thigh
was divided into three compartments (anterior, poster-
ior, medial) (Figure 1). A compartment was considered
positive for muscular injury when an area of high signal
intensity on T2-weighted and STIR sequences was ob-
served in at least one muscle.
Muscle biopsies
Muscle biopsies were performed 48 hours after exercise
to obtain samples for the analysis of markers of cellular
injury (muscle myeloperoxidase [MPO] activity, immuno-
histochemical analysis of albumin [38] and CD3 positive
cells). A skin incision was performed with a 5 mm blade.
The same skin incision was used for both muscle biopsies,
changing the needle direction [34,39]. Two biopsies were
carried out from the middle third of each vastus lateralis,
under ultrasound control. Muscle samples were obtained
using a Vacora System Biopsy gun (Bard Medical Systems,
Tempe, AZ, USA), with a coaxial needle of 10G ×
140 mm. With this technique the sample is aspirated
and remains in the branula until it is extracted; the sam-
ple is taken out as a whole and not fragmented. Once
the samples were extracted, they were kept in formol,
glutaraldehyde and a third sample was cryopreserved
at -80°C for further studying [40].risk marks muscle area with increased uptake.
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were first dissected free of visible connective tissue and fat
and embedded in paraffin using conventional methods.
Ten-micrometre sections were cut, varying the inclination
of the holder by 5-degree increments until the minimum
cross-sectional area was obtained, which was defined as
truly transverse.
Evaluation of sarcolemmal disruptions
Evaluation of sarcolemmal disruption relies on the ob-
servation that cellular membrane permeability to albu-
min is a sign of membrane injury [41]. For assessment
and quantification of muscle membrane injury, we chose
a method based on light microscopy for identification of
fibres that contain albumin by immunohistochemistry.
Each sample was processed for immunohistochemical
techniques using a polyclonal rabbit anti-human anti-
body directed against albumin (Code No. A0001; Dako
Cytomation, DK-2600 Glostrup, Denmark) as a primary
antibody. This immunocomplex was detected using a
horseradish peroxidase-labelled goat anti-rabbit second-
ary antibody (Code No. K4003; EnVision + System-HRP
labelled polymer, Dako Co., Carpinteria, CA, USA). The
reaction was developed with a chromogen solution with
3.3-diaminobenzidine (Code No. K3468; Liquid DAB +
Substrate-Chromogen Solution, Dako Co., Carpinteria,
CA, USA). The analysis of intracellular albumin was per-
formed by two independent observers using a categorical
scale (0–3) with a light microscope (Olympus, Series
AX70TF; Olympus Optical Co., Shinjukuku, Tokyo, Japan)
coupled with an image-digitizing camera (View Finder
Lite; Version 1.0.143c; Pixera Co., Los Gatos, CA) and a
morphometry program (Scion Image, Version Beta 4.0.2;
Scion Co., Frederick, MD, USA). Qualification of fibre
injury was performed in a four-category finite interval
system, the extremes representing either the absence of
intracellular albumin (i.e., absence of sarcolemmal in-
jury, degree 0), or presence of intracellular albumin on
the complete cellular area (i.e., severe sarcolemmal in-
jury, degree 3). The two intermediate categories were
classified as degree 1 injury (i.e., mild sacolemmal injury
or presence of albumin in less than 50% of the fibre
area) and degree 2 injury (i.e., moderate sarcolemmal
injury or presence of albumin on more than 50% of the
fibre area, but not in all of it). Fibre categories were
expressed as proportion (%) of total muscle fibres. The
mean value of degree 2 and degree 3 obtained by two
observers was used for statistical analysis [42,43].
CD3+ and MPO immunohistochemical staining
For the assessment and quantification of CD3+ and MPO
intra/interfibrillar infiltrates we chose a method based on
light microscopy for identification of CD3+ and MPO
by immunohistochemistry. For the immunohistochemicalassay we used manual immunostaining. For MPO a poly-
clonal rabbit antihuman antibody directed against MPO
(Dako Ref. IS511, 1:4 dilution, prediluted), and for CD3+ a
polyclonal rabbit anti-human directed against MPO
(Dako Ref. A0452, 1:250 dilution), were used as a pri-
mary antibodies. For MPO antigen retrieval, the sec-
tions were deparaffinized, rehydrated in gradually
decreasing concentrations of ethanol, PBS (3x5’), citrate
7,3 retrieval, pressure cooker, PBS (3x5’), hydrogen per-
oxide 10’ at room temperature, PBS (3x5’), primary anti-
body 30’ at room temperature 1:4 dilution, PBS (3x5’),
secondary antibody Envison 30’ at room temperature,
PBS (3x5’), DAB (1 drop for 1 ml dilute) 5/10 minutes
at room temperature, PBS (3x5’), Mayer haematoxylin
10’ at room temperature, water, dehydration, D.P.X. as-
sembly, visualization with Envison/HRP Dako (Glostrup,
Denmark). For CD3+ antigen retrieval, the sections were
deparaffinized, rehydrated in gradually decreasing concen-
trations of ethanol, PBS (3x5’), citrate 7,3 retrieval, pres-
sure cooker, PBS (3x5’), hydrogen peroxide 10’ at room
temperature, PBS (3x5’), primary antibody 30’ at room
temperature 1:250 dilution, PBS (3x5’), secondary antibody
Envison 30’ at room temperature, PBS (3x5’), DAB (1 drop
for 1 ml dilute) 5/10 minutes at room temperature, PBS
(3x5’), Mayer haematoxylin 10’ at room temperature,
water, dehydration, D.P.X. assembly, visualization with
Envison/HRP Dako (Glostrup, Denmark). The lympho-
cytic infiltrates (CD3+) and MPO were quantified fol-
lowing the total number of T cells immunostained
antibodies against CD3+, and MPO. The total number
of CD3+ cells, and the total number of fibres were
counted blindly by two observers, and were used for
statistical analysis. CD3+ cells per fibre was calculated
and compared between PT and CT40. Number of fibres
with MPO was evaluated in the same way [35,44]. The
testing laboratory was blinded to treatment allocation.
Laboratory analyses
One week prior to the study day, routine laboratory
analyses (complete blood count, erythrocyte sedimenta-
tion rate [ESR], C-reactive protein [CRP], aspartate ami-
notransferase [AST], alanine aminotransferase [ALT],
gamma glutamyl transferase [GGT], alkaline phosphatase,
urea, creatinine, uric acid, total cholesterol, HDL-C, LDL-
C, triglycerides, sodium, calcium, magnesium, vitamin D,
serum iron, transferrin, ferritin) were performed to assess
eligibility.
Oxidative stress and inflammatory markers
Blood samples were collected immediately before the
downhill running test and 2 and 24 hours after the ex-
ercise for the measurement of CRP, high-sensitivity
CRP (hsCRP), ERS, interleukin-8 (IL-8), monocyte chemo-
attractant protein-1 (MCP-1), ferric reducing ability of
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ase (GPx). Creatine kinase (CK) was used as a marker of
muscle damage.
Pain intensity
Pain intensity was assessed 48 hours after downhill run-
ning. Patients were asked to indicate the site of pain on
a drawing representing the lower limbs, and to rank
pain intensity on a 0–4 point scale, where 0 = no pain
and 4 = disabling pain when descending or climbing
stairs. The scores relative to different sites on each side
of the thigh and leg were summed to obtain a total score
for each segment of the lower limb (anterior right thigh,
posterior right thigh, anterior right leg, posterior right
leg, anterior left thigh, posterior left thigh, anterior left
leg and posterior left leg).
Statistical analyses
Data are expressed as means ± SD [95% confidence
interval]. Between- and within-group changes in IL-8,
MCP-1, CK, ESR, CRP, hsCRP, FRAP, CAT and GPx
levels were analysed with a two-way mixed-design ana-
lysis of variance (ANOVA) followed by Tukey-Kramer
test for pairwise comparisons. Pain scores and albumin,
MPO, CD3+ cells were analysed by the Hotelling’s T2 test.
The Pearson’s Chi squared test was used to analyse data
obtained from the MRI. Significance was set at p < 0.05.
Results
Study participants
Nineteen subjects out of twenty completed the study.
One subject in the Meriva® group dropped out before
the injury test phase by personal decision. Baseline char-
acteristics of participants are presented in Table 1. There
were no statistically significant differences between sub-
jects in the placebo (n = 10) and the Meriva® (n = 9) group.
Maximal speed reached during the maximal exercise test
was 13.7 ± 1.8 [12.4;15.9] and 14.8 ± 1.1 [13.9;15.6] km/h
in the placebo and Meriva® group, respectively (p = ns).
During the downhill running test subjects treated withTable 1 Subjects’ baseline characteristics
Placebo (n = 10)
Mean ± SD
Age (years) 38.1 ± 11.1
Height (cm) 174.8 ± 3.0
Weight (kg) 75.8 ± 6.5
BMI (kg/m2) 24.8 ± 1.7
VO2/kg (ml/kg) 45.8 ± 4.7
Maximal speed (maximal exercise test) (km/h) 13.7 ± 1.8
Speed at the anaerobic threshold (km/h) 10.9 ± 1.7
Speed during the injury provocation test (km/h) 10.9 ± 1.2placebo and Meriva® were able to maintain a speed of
10.9 ± 1.2 [10.0;11.7] and 11.4 ± 0.9 [10.8;11.4] km/h,
respectively, for 45 minutes, which was comparable to
the speed at the anaerobic threshold (Table 1).
Imaging studies
Overall, the number of subjects with MRI evidence of
muscle injury was similar in the two groups. However,
the proportion of subjects with MRI evidence of muscle
injury in the posterior or medial compartment of the
right thigh was significantly lower in the Meriva® group as
compared to the placebo group (44.4% vs. 90%, p = 0.0329
and 33.3% vs. 80%, p = 0.0397) (Figure 2). Similarly, less
subjects in the Meriva® group had MRI evidence of muscle
injury in the posterior or medial compartment of the
left thigh (33.3% vs. 80%, p = 0.0397 and 33.3% vs. 90%,
p = 0.0106) (Figure 2).
Pain intensity
Subjects in the curcumin group reported less pain in
the lower limb as compared with subjects in the placebo
group (total score: 23.3 ± 7.9 [17.2;29.4] vs. 30.6 ± 7.9
[24.9;36.2], p = 0.06) (Figure 3). However, this difference
did not reach statistical significance. Similarly, the ana-
lysis of each segment considered revealed a trend for
less pain in the Meriva® group, but a statistically signifi-
cant difference was observed only for the right and left
anterior thighs (4.4 ± 2.5 [2.6;6.3] vs. 7.8 ± 3.9 [5.0;10.6]
and 4.4 ± 2.4 [2.6;6.2] vs. 8.2 ± 4.6 [4.9;11.5] in the Meriva®
and placebo group, respectively; p < 0.05).
Markers of muscle injury and inflammation
CK levels significantly increased from baseline in
both groups, confirming the presence of muscle injury
(Figure 4A). Although CK levels tended to increase less in
the Meriva® group, this difference did not reach statistical
significance. hsPCR levels paralleled the increase in CK,
and significantly increased from baseline in both groups
(Figure 4B). However, at 24 hours the percent increase
from baseline was numerically lower in the Meriva® group95% CI Curcumin (n = 9)
Mean ± SD
95% CI
30.1;46.1 32.7 ± 12.3 23.1;42.1
172.7;176.9 176.6 ± 3.6 173.7;179.4
71.2;80.4 76.2 ± 4.2 73.0;79.5
23.6;26.0 24.4 ± 1.0 23.6;25.2
42.5;49.2 48.9 ± 5.3 44.8;53.1
12.4;15.0 14.8 ± 1.1 13.9:15.6
6.6;12.1 11.8 ± 1.5 10.6;12.9
10.0;11.7 11.4 ± 0.9 10.8;11.4
Figure 2 MRI evidence of muscular injury. Percent of subjects
with MRI evidence of muscular injury. ART, anterior right thigh; PRT,
posterior right thigh; MRT, medial right thigh; ALT, anterior left thigh;
PLT, posterior left thigh; MLT, medial left thigh. *p < 0.05 for
curcumin vs placebo.
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p = ns). IL-8 levels tended to remain stable in the Meriva®
group, whereas a steep increase was observed at 2 hours
in the placebo group (Figure 4C). At this time point, IL-8
was significantly lower in the Meriva® group (196.8 ± 66.1
[146.4;247.1] vs. 274.7 ± 70.7 [226.8;322.4] pg/mL, p < 0.05).
No significant differences were observed in MCP-1 levels
between the two groups (Figure 4D).
Oxidative stress
Both groups experienced a modest increase in markers
of oxidative stress. FRAP levels did not show significant
changes over time, whereas CAT and GPx levels tended
to increase at 2 hours after exercise and returned towards
baseline values at 24 hours. These trends were similar
in both groups.
Muscle biopsies
Muscle samples were available for four subjects in the
curcumin group and five subjects in the placebo group.Figure 3 Pain intensity. Patient-reported pain intensity in the right
thigh (RT), left thigh (LT), right leg (RL), left leg (LL) and total pain
score (the sum of the scores of each lower limb).No significant differences were observed between the
two groups with regard to sarcolemmal disruption and




In the present study we sought to investigate the effects of
curcumin on damage from oxidative stress and inflamma-
tion related to acute muscle injury induced by eccentric
continuous exercise. We found that curcumin supplemen-
tation reduced MRI evidence of muscle injury in the pos-
terior or medial compartment of the thighs and was
associated with a trend for less pain in the lower limb and
a blunted systemic inflammatory response as compared
with placebo. Several mechanisms might be responsible
for the favourable effects that curcumin had on exercise-
induced muscle injury in this study, but the most plausible
are related to the antioxidant properties of curcumin.
However, there is considerable confusion on the role of
“antioxidant” supplementation and exercise. In fact, sup-
plementation with vitamin C has been shown to decrease
the development of endurance capacity [45] and the view
that exercise and antioxidants might work against each
other was also suggested by studies showing that anti-
oxidant supplementation abrogates the beneficial effects
of exercise on insulin resistance [46]. Since exercise in-
creases consumption of oxygen and mitochondrial activity,
ROS might, paradoxically, mediate not only cellular dam-
age associated to exercise, but also its beneficial effect.
Direct anti-oxidants like vitamin C and vitamin E were
used in these “negative” anti-oxidant studies. These com-
pound directly react and quench free radicals and ROS,
while curcumin and phenolics are essentially boosters of
the body’s endogenous antioxidant response, and exert
“antioxidant” activity indirectly, by Nrf2-mediated stimula-
tion of the cellular antioxidant system and the expression
of cytoprotective genes.
Effect of curcumin on oxidative stress and inflammation
Since curcumin can both stimulate the endogenous anti-
oxidant response via Nrf2 activation and moderate inflam-
matory response via NF-kB inhibition, it could in principle
be useful to increase tissue resistance to ROS while at the
same time not interfering with the beneficial metabolic ef-
fects associated to their generation. In this context, it was
therefore interesting to evaluate if supplementation with
curcumin, administered as a Phytosome® delivery system
(Meriva®) to promote absorption, could affect DOMS in-
duced by eccentric exercise. To the best of our knowledge,
this is the first study to investigate the effects of curcumin
on DOMS in humans. In a previous study, curcumin sup-
plementation was shown to improve the inflammatory
pattern and markers of muscle injury, ameliorating the
Figure 4 Markers of muscle damage and inflammation. A. Creatine kinase (CK), B. high-sensitivity CRP (hsCRP), C. interleukin-8 (IL-8) and
D. monocyte chemoattractant protein-1 (MCP-1) levels measured at baseline and 2 and 24 hours after the downhill running test. *p < 0.05.
Figure 5 Sarcolemmal damage and acute inflammatory response
to exercise. CD3+, CD positive cells; MPO, myeloperoxidase.
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muscle damage [31]. We found that significantly less
subjects in the Meriva® group had MRI evidence of
muscle injury in the posterior or medial compartment
of both thighs 48 hours after exercise, and a trend for
lower pain intensity (p = 0.06) in the lower limb was ob-
served in subjects receiving curcumin, with a statisti-
cally significant difference versus placebo for the right
and left anterior thighs. These findings suggest that cur-
cumin might be beneficial in the prevention of DOMS.
However, one might argue that, being a mild inhibitor
of cyclooxygenase 1/2 (COX1/2) [47,48], curcumin may
interfere with muscle growth. In fact, the detrimental ef-
fects of non-steroidal antinflammatory drugs (NSAIDs),
which are known inhibitors of COXs, are an important
point of concern [49]. This effect is mediated by the inhib-
ition of COXs, and COX2 in particular, and seems typical
Drobnic et al. Journal of the International Society of Sports Nutrition 2014, 11:31 Page 8 of 10
http://www.jissn.com/content/11/1/31of all agents active on these pro-inflammatory end-points.
Curcumin is a poor inhibitor of COX1/2, and its effects
on the production of prostaglandins are essentially due to
the inhibition of the (mPGES)-1 [50], the inducible
form of the ultimate enzyme involved in the generation
of the single specific prostaglandin PGE2. Inhibition of
(mPGES)-1 has not been related to interference with
muscle growth, that seemingly results from the global
depletion of prostanoids associated to the inhibition of
“uphill” enzymes involved in their generation, like COXs.
Conversely, PGE2 is considered one of the markers of
muscle damage induced by exercise [51].
Analgesic effect of curcumin
In a previous study that evaluated the analgesic efficacy
of the same formulation (Meriva® 2 g, corresponding to
curcumin 400 mg) taken as needed in patients with
acute pain, curcumin had a well-defined pain-relieving
effect, even greater than that of acetaminophen 500 mg,
and was better tolerated than nimesulide [23]. This acute
effect is probably related to the desensitization or the
inhibition of a series of transient receptor potential ion
channels involved in the generation of painful stimuli
like TRPV1 and TRPA1 [52,53]. In that study, the anal-
gesic effect of curcumin lasted for approximately 4 hours,
and a second dose, administered 6–12 hours after the
first dose, was necessary for controlling pain in some
cases [23]. In our study, Meriva® was administered at a
dose of 1 g (delivering 200 mg curcumin) twice daily for
four days, starting 48 hours prior to the exercise test and
until 24 hours after exercise. The pain relieving effect of
Meriva® could be mediated by a modulation of the in-
flammatory and oxidative responses to muscle injury.
Muscle injury in DOMS appears to be related to inflam-
mation and oxidative stress leading to neutrophil accu-
mulation, increases in oxidative enzymes, cytokines and
chemokines [9-11]. A significant increase in CK levels
over 24 hours in both groups validated the protocol used
in this study as an inductor of muscle damage. This in-
crease was moderated by supplementation with Meriva®,
that also led to lower levels of hsPCR and IL-8 2 hours after
exercise. Several studies have confirmed that curcumin
down-regulates the expression of several pro-inflammatory
cytokines involved in proteolysis and muscle inflamma-
tion [25] by suppressing NF—κB signalling [54,55]. This
mechanism could also be responsible for the reduced
inflammatory response to exercise observed in this
study.
Study limitations
It should be acknowledged that the findings of this study
may be limited to aerobic exercise, since different types
of exercise (e.g., aerobic and resistance exercise) elicit
unique molecular responses, and the effects of ROS inmuscle may vary depending on the type of exercise in-
volved [49]. Furthermore, markers of oxidative stress were
only slightly increased after exercise in both groups, which
does not allow a comparison of the effects of curcumin
versus placebo. The failure to observe differences in tissue
markers of sarcolemmal disruption and inflammatory
response between the two groups of volunteers might
be due the small number of muscle samples available
for analysis. Previous positive studies on curcumin sup-
plementation for chronic musculoskeletal conditions like
osteoarthritis [22,56] involved longer treatments (3–8
months), and it might therefore be that supplementa-
tion in this study was too short to produce statistically
significant histological benefits over placebo.
Conclusions
Taken together, our observations suggest that curcumin
may be beneficial to attenuate exercise-induced DOMS,
and larger studies could provide statistical significance
also for the functional and biochemical parameters that
only showed a trend to improvement in our study, like
the histological evaluation of muscle damage.
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